MIMEDX to acquire Sanara MedTech in $350M deal to double surgical revenue
What's the deal? MIMEDXDealroom has a profile for this one. Try Dealroom → (Nasdaq: MDXG) will acquire Sanara MedTechDealroom has a profile for this one. Try Dealroom → (Nasdaq: SMTI) in a cash-and-stock transaction valued at $35 per share, giving Sanara an enterprise value of about $350 million. The price marks a 46% premium to Sanara's 30-day volume-weighted average price.
Sanara holders will receive $33.00 in cash plus 0.4735 MIMEDX shares for each Sanara share. Both boards unanimously approved the deal, which is expected to close by the end of 2026, subject to Sanara shareholder and regulatory approvals.
What's the endgame? Both companies operate in wound care and surgical products. MIMEDX expects the combination to nearly double its surgical revenue and generate more than $20 million in run-rate cost synergies.
The numbers: The companies project 2027 combined revenue above $400 million, with an adjusted EBITDA margin over 20%. MIMEDX says the deal will be immediately accretive to revenue growth and margins.
How it's funded: MIMEDX plans to cover the cash portion with cash on hand and a new $300 million term loan from Hayfin Capital ManagementDealroom has a profile for this one. Try Dealroom →. The loan replaces its existing credit facility, which will be terminated and repaid in full.
The signal: The tie-up reflects continued consolidation in wound care and surgical products, as mid-cap medtech firms combine to scale revenue and widen margins.
Read more: StockTitan
